Literature DB >> 20031602

Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy.

Carolyn Y Ho1, Christian Carlsen, Jens Jakob Thune, Ole Havndrup, Henning Bundgaard, Faranak Farrohi, Jose Rivero, Allison L Cirino, Paal Skytt Andersen, Michael Christiansen, Barry J Maron, E John Orav, Lars Køber.   

Abstract

BACKGROUND: Genetic testing identifies sarcomere mutation carriers (G+) before clinical diagnosis of hypertrophic cardiomyopathy (HCM), allowing characterization of initial disease manifestations. Previous studies demonstrated that impaired relaxation develops before left ventricular hypertrophy (LVH). The precise impact of sarcomere mutations on systolic function in early and late disease is unclear. METHODS AND
RESULTS: Comprehensive echocardiography with strain imaging was performed on 146 genotyped individuals with mutations in 5 sarcomere genes. Contractile parameters were compared in 68 preclinical (G+/LVH-), 40 overt (G+/LVH+) subjects with HCM, and 38 mutation (-) normal control relatives. All subjects had normal left ventricular ejection fraction. In preclinical HCM, global and regional peak systolic strain (epsilon(sys)) and longitudinal systolic strain rate were not significantly different from controls, but early diastolic mitral annular velocity (Ea) was reduced by 13%. In overt HCM, there was a significant 27% and 14% decrease in global longitudinal epsilon(sys) and systolic strain rate, respectively, compared with both preclinical HCM and controls (P<0.013 for all comparisons), and a 33% reduction in Ea.
CONCLUSIONS: Sarcomere mutations have disparate initial effects on diastolic and systolic functions. Preclinical HCM is characterized by impaired relaxation but preserved systolic strain. In contrast, both diastolic and longitudinal systolic abnormalities are present in overt disease despite normal ejection fraction. We propose that diastolic dysfunction is an early consequence of sarcomere mutations, whereas systolic dysfunction results from mutations combined with subsequent pathological remodeling. Identifying mechanistic pathways triggered by these mutations may begin to reshape the clinical paradigm for treatment, based on early diagnosis and disease prevention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031602      PMCID: PMC2773504          DOI: 10.1161/CIRCGENETICS.109.862128

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  29 in total

1.  Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle.

Authors:  Stian Langeland; Jan D'hooge; Patrick F Wouters; H Alex Leather; Piet Claus; Bart Bijnens; George R Sutherland
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

2.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

3.  Assessment of passive elastic stiffness for isolated heart muscle and the intact heart.

Authors:  I Mirsky; W W Parmley
Journal:  Circ Res       Date:  1973-08       Impact factor: 17.367

4.  The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation.

Authors:  D Georgakopoulos; M E Christe; M Giewat; C M Seidman; J G Seidman; D A Kass
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

5.  Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families.

Authors:  W J McKenna; P Spirito; M Desnos; O Dubourg; M Komajda
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

6.  Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  M Spindler; K W Saupe; M E Christe; H L Sweeney; C E Seidman; J G Seidman; J S Ingwall
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

7.  Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography.

Authors:  Tomoko S Kato; Akiko Noda; Hideo Izawa; Akira Yamada; Koji Obata; Kohzo Nagata; Mitsunori Iwase; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Circulation       Date:  2004-12-06       Impact factor: 29.690

Review 8.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; J G Seidman; Christine E Seidman
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

9.  Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  E Blanchard; C Seidman; J G Seidman; M LeWinter; D Maughan
Journal:  Circ Res       Date:  1999-03-05       Impact factor: 17.367

10.  Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study.

Authors:  S J Dong; J H MacGregor; A P Crawley; E McVeigh; I Belenkie; E R Smith; J V Tyberg; R Beyar
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

View more
  52 in total

1.  Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?

Authors:  Gloria Maria Santambrogio; Alessandro Maloberti; Paola Vallerio; Angelica Peritore; Francesca Spanò; Lucia Occhi; Francesco Musca; Oriana Belli; Benedetta De Chiara; Francesca Casadei; Rita Facchetti; Fabio Turazza; Emanuela Manfredini; Cristina Giannattasio; Antonella Moreo
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-18       Impact factor: 2.357

2.  The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.

Authors:  Carolyn Y Ho; John J V McMurray; Allison L Cirino; Steven D Colan; Sharlene M Day; Akshay S Desai; Steven E Lipshultz; Calum A MacRae; Ling Shi; Scott D Solomon; E John Orav; Eugene Braunwald
Journal:  Am Heart J       Date:  2017-02-16       Impact factor: 4.749

Review 3.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

4.  Relationship of Echocardiographic Z Scores Adjusted for Body Surface Area to Age, Sex, Race, and Ethnicity: The Pediatric Heart Network Normal Echocardiogram Database.

Authors:  Leo Lopez; Steven Colan; Mario Stylianou; Suzanne Granger; Felicia Trachtenberg; Peter Frommelt; Gail Pearson; Joseph Camarda; James Cnota; Meryl Cohen; Andreea Dragulescu; Michele Frommelt; Olukayode Garuba; Tiffanie Johnson; Wyman Lai; Joseph Mahgerefteh; Ricardo Pignatelli; Ashwin Prakash; Ritu Sachdeva; Brian Soriano; Jonathan Soslow; Christopher Spurney; Shubhika Srivastava; Carolyn Taylor; Poonam Thankavel; Mary van der Velde; LuAnn Minich
Journal:  Circ Cardiovasc Imaging       Date:  2017-11       Impact factor: 7.792

5.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

6.  Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy.

Authors:  Mohamed F A Aly; Wessel P Brouwer; Sebastiaan A Kleijn; Albert C van Rossum; Otto Kamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

7.  Morphological and functional abnormalities pattern in hypertrophy-free HCM mutation carriers detected with echocardiography.

Authors:  Jérôme Peyrou; Patricia Réant; Amélie Reynaud; Claire Cornolle; Marina Dijos; Caroline Rooryck-Thambo; Mathieu Landelle; Michel Montaudon; François Laurent; Raymond Roudaut; Stéphane Lafitte
Journal:  Int J Cardiovasc Imaging       Date:  2016-06-20       Impact factor: 2.357

8.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

Review 9.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

10.  Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.

Authors:  Pranoti Hiremath; Patrick R Lawler; Jennifer E Ho; Andrew W Correia; Siddique A Abbasi; Raymond Y Kwong; Michael Jerosch-Herold; Carolyn Y Ho; Susan Cheng
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.